Important Deadline Approaching for Geron Corporation Securities Investors Considering Class Action Lawsuit

Geron Corporation Class Action Lawsuit: A Call to Investors

Geron Corporation, a biopharmaceutical firm known for its innovative treatments in oncology, is currently facing a class action lawsuit surrounding its securities. Investors who acquired shares between February 28, 2024, and February 25, 2025, are urged to take action as the deadline to appoint a lead plaintiff is fast approaching on May 12, 2025.

Background of the Class Action

The law firm Robbins Geller Rudman & Dowd LLP is spearheading the class action, which is titled Dabestani v. Geron Corporation, No. 25-cv-02507 (N.D. Cal). This lawsuit alleges that Geron and its executives made misleading statements that violated the Securities Exchange Act of 1934. This comes in the wake of the company’s disappointing financial results for the last quarter of 2024, where they revealed that anticipated growth was not met due to a myriad of challenges, including competition and internal operational issues.

Claims Against Geron

The crux of the allegations is that the defendants created a distorted impression regarding their knowledge of the expected financial performance and market environment of Geron’s lead product, Rytelo, a telomerase inhibitor. Key claims include:

1. Misrepresentation of Revenue Outlook: During the class period, the company provided false assurances that their forecasts regarding revenue and growth were based on solid and reliable data. Contrary to this, essential factors such as seasonal impacts and competition were downplayed.

2. Inadequate Market Penetration: Reports indicate that Rytelo struggled to develop market awareness sufficient to meet its potential, particularly among first-line patients and beyond academic settings. This lack of penetration has greatly affected Geron’s capability to capitalize on the drug's purported demand.

3. Impact of Recent Financial Results: The issues culminated on February 26, 2025, when Geron disclosed poor financial performance, which led to a steep drop in its stock price by over 32%. This revelation highlighted the gap between the company’s optimistic reports and the harsh realities of market dynamics.

The Lead Plaintiff Process

Under the Private Securities Litigation Reform Act, any investor who purchased or sold Geron securities within the defined period can seek to participate as the lead plaintiff in the class action. The selection criteria prioritize those with the most significant shareholdings that reflect the collective interest of all investors.

A lead plaintiff plays an integral role, guiding the litigation process and collaborating with the chosen legal representation to ensure the best outcome for the class involved. Moreover, fulfilling the role of lead plaintiff does not hinder an investor’s chance of compensatory relief if they choose not to take on that responsibility.

Robbin Geller’s Credentials

Robbins Geller Rudman & Dowd LLP is recognized as one of the preeminent law firms representing investors in securities fraud cases. The firm has a proven track record of securing significant financial reimbursement for its clients, ranking at the top in the ISS Securities Class Action Services rankings for several consecutive years.

Moreover, in 2024 alone, the firm managed to recover an impressive $2.5 billion for investors through various securities-related class action lawsuits. Their extensive experience positions them to advocate effectively on behalf of both lead plaintiffs and the broader class of investors.

How to Take Action

If you’re an investor affected by the developments surrounding Geron Corporation, it’s crucial to act promptly. For guidance, legal advice, or to register your interest in taking part in the class action lawsuit, contact Robbins Geller at their San Diego office or visit their dedicated webpage for more information.

This is a critical opportunity to ensure that your voice as an investor is heard and to seek justice for the financial losses incurred. Don’t miss the upcoming deadline of May 12, 2025, to position yourself as a lead plaintiff in this significant case.

For further assistance, you may reach out to attorneys J.C. Sanchez or Jennifer N. Caringal at 800/449-4900 or email [email protected].